Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71130 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Kristina Pigsborg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Albuminuria, Diabetes Mellitus, Type 2, Ceramides, Cardiovascular Diseases. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Foundation (NNF).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD. We assessed the effect of four albuminuria‐lowering drugs on CVD‐related ceramides in diabetes by post hoc analysis of the ROTATE trials. Materials and Methods Twenty six adults with type 1 (T1D) as well as 37 with type 2 diabetes (T2D) with a urine albumin‐creatinine ratio (UACR) of 30–500 mg/g participated in a 4‐week 4‐time randomized crossover study with periods of telmisartan, empagliflozin, linagliptin and baricitinib treatment, each separated by a 4‐week washout period. Blood samples were collected at the beginning and end of each period and ceramide lipids (Cer16, Cer18, Cer20, Cer22, Cer24 and Cer24:1) were measured. The effect of each treatment was evaluated using linear mixed‐effect models.
Results
At baseline, individuals with T2D had greater levels of Cer22 and Cer24 compared to the individuals with T1D. Among the treatments, linagliptin was the only drug that demonstrated a reduction of Cer22, Cer24 and Cer24:1 from baseline by 22.6% (95% CI: −33.58; −9.79, p = 0.001), 25.7% (95% CI: −38.94; −9.69, p = 0.003) and 19.6% (95% CI: −31.34; −5.95, p = 0.007), respectively. No changes in the ceramides were observed for the other drugs.
Conclusion
Our exploratory findings suggest that certain albuminuria‐lowering drugs may affect ceramide levels as a secondary effect. However, further mechanistic investigations are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Department of Clinical Medicine and Diabetes, Novo Nordisk Foundation, Hellerup, Denmark.
- Institute of Pharmaceutical Science, King's College London, London, UK.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- GLP-1 Center of Excellence, Research and Early Development, Novo Nordisk A/S, Måløv, Denmark.
ORCID-Profile: Simon Maria Kienle, Viktor Rotbain Curovic, Hiddo J L Heerspink, Tine Willum Hansen, Cristina Legido-Quigley, Peter Rossing
Förderung
- Novo Nordisk Foundation (NNF)
Zitieren
APA
Pigsborg, K., Kienle, S. M., Wretlind, A., Rotbain Curovic, V., Blond, M. B., Heerspink, H. J. L., Hansen, T. W., Persson, F., Sulek, K., Legido-Quigley, C., & Rossing, P. (2026). Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71130
Vancouver
Pigsborg K, Kienle SM, Wretlind A, Rotbain Curovic V, Blond MB, Heerspink HJL, et al. Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71130
BibTeX
@article{Pigsborg2026,
author = {Pigsborg, Kristina and Kienle, Simon Maria and Wretlind, Asger and Rotbain Curovic, Viktor and Blond, Martin Bæk and Heerspink, Hiddo J L and Hansen, Tine Willum and Persson, Frederik and Sulek, Karolina and Legido-Quigley, Cristina and Rossing, Peter},
title = {Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71130}
}
EUVIMED